This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read 89bio’s 8K filing here.
89bio Company Profile
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
Featured Stories
- Five stocks we like better than 89bio
- Insider Buying Explained: What Investors Need to Know
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Options Trading – Understanding Strike Price
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- The 3 Best Retail Stocks to Shop for in August
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
